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SUMMARY
Defining the molecular networks that drive breast
cancer has led to therapeutic interventions and
improved patient survival. However, the aggressive
triple-negative breast cancer subtype (TNBC) re-
mains recalcitrant to targeted therapies because its
molecular etiology is poorly defined. In this study,
we used a forward genetic screen to discover an
oncogenic network driving human TNBC. SCYL1,
TEX14, and PLK1 (‘‘STP axis’’) cooperatively trigger
degradation of the REST tumor suppressor protein,
a frequent event in human TNBC. The STP axis in-
duces REST degradation by phosphorylating a
conserved REST phospho-degron and bridging
REST interaction with the ubiquitin-ligase bTRCP. In-
hibition of the STP axis leads to increased REST pro-
tein levels and impairs TNBC transformation, tumor
progression, and metastasis. Expression of the STP
axis correlates with lowREST protein levels in human
TNBCs and poor clinical outcome for TNBC patients.
Our findings demonstrate that the STP-REST axis is a
molecular driver of human TNBC.
INTRODUCTION
Breast cancer is a heterogeneous disease comprising three clin-
ical subtypes: estrogen receptor positive (ER+), HER2 positive
(HER2+), and triple-negative breast cancer (TNBC). The identifi-
cation of prominent molecular drivers of breast cancers (ER and
HER2) has enabled the development of targeted therapies that
have improved survival rates for patients with ER+ and HER2+
breast cancers (Arteaga et al., 2012; Osborne, 1998; Slamon
et al., 1989). In contrast, there are currently no effective targeted
therapies for patients with TNBC, which exhibit a poor prognosis
due to high frequency of early relapse andmetastasis (Di Cosimo
andBaselga, 2010; Hurvitz and Finn, 2009). Themolecular deter-
minants driving TNBC are poorly understood, and this paucity in
our understanding of pathways governing TNBC pathogenesis
remains a major obstacle to developing therapies for TNBC
patients.
The RE-1 silencing transcription factor (REST) was originally
discovered as a transcriptional repressor of neural and neuronal
genes (Chong et al., 1995; Schoenherr and Anderson, 1995). As
a master regulator of neuronal gene programs, REST plays an
important role in neural differentiation and has been suggested
to restrain these programs in nonneuronal tissues (Ballas and
Mandel, 2005). Surprisingly, REST also functions as a tumor
suppressor in epithelial cancers (Westbrook et al., 2005),
although the mechanisms by which REST restrains tumorigen-
esis remains undefined. Consistently, REST is frequently inacti-
vated in epithelial malignancies such as colon and lung cancer
via gene deletion, inactivating mutations (Westbrook et al.,
2005), epigenetic silencing (Kreisler et al., 2010), and rarely
through alternative splicing (Coulson et al., 2000; Wagoner
et al., 2010). However, although REST potently suppresses
transformation of cells derived frommammary epithelium (West-
brook et al., 2005), it has remained unclear whether REST is in-
activated in breast cancer and what the molecular mechanisms
of such misregulation might be.
The REST protein exhibits rapid turnover and is precisely regu-
latedduring neural development via theubiquitin ligaseSCFbTRCP
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and proteasomal degradation (Ballas et al., 2005). Like many
SCFbTRCP substrates (Fuchs et al., 2004; Petroski and Deshaies,
2005;Winston et al., 1999), RESTmust be phosphorylated within
a C-terminal phosphodegron for recognition, ubiquitylation, and
subsequentdegradation (Guardavaccaro et al., 2008;Westbrook
et al., 2008), suggesting REST stability is regulated by upstream
kinase(s) that prime SCFbTRCP-mediated degradation. In this
study, we report that REST protein is frequently lost through
aberrant degradation in human breast cancer, most prevalently
in TNBC. Using an unbiased genetic screen, we identified
SCYL1, TEX14, and PLK1 as components of an oncogenic
signaling axis (the STP axis) that prominently regulates REST
abundance and stability. The STP axis supports cellular
transformation, and inhibition of STP components leads to
REST protein accumulation and impairment of TNBC at primary
and metastatic sites. Collectively, this study uncovers the STP
axis as a prominent regulator of REST stability and TNBC
pathogenesis.
RESULTS
REST Is Posttranscriptionally Inactivated in Human
Breast Cancer
The REST tumor suppressor restrains cell transformation and is
frequently inactivated by genetic and epigenetic mechanisms in
epithelial cancers (Kreisler et al., 2010;Westbrook et al., 2005). In
contrast, whereas REST potently suppresses transformation of
mammary epithelium (Westbrook et al., 2005), analysis of public
sequencing and copy-number data indicate that REST is not
frequently deleted or mutated in human breast cancer (data
not shown). To determine whether REST is compromised by
alternative mechanisms in human breast cancer, we evaluated
REST protein levels in primary human breast tumors (n = 185)
(Figures 1A and S1A). REST protein was readily detectable in
all normal mammary tissue analyzed (n = 8) and in normal mam-
mary gland adjacent to tumor tissue (representative images in
Figures 1A, S1B, and S1C). In contrast, REST protein was unde-
tectable in 19% of human breast cancers (Figures 1B and 1C).
Strikingly, REST protein levels were lowest in TNBC (Figure 1B),
with 32% of TNBCs exhibiting undetectable REST protein (Fig-
ure 1C), suggesting REST dysfunction is a common pathogenic
event in this aggressive subtype of breast cancer.
Because REST protein is frequently undetectable in TNBC and
other breast cancers, we examined the mechanism by which
REST protein is lost. Analysis of REST mRNA in primary human
breast cancers revealed that REST mRNA was detectable in all
samples analyzed (n = 50) and did not correlate with REST pro-
tein levels (Figure 1D), suggesting REST is posttranscriptionally
depleted in human breast cancer. Previous studies have de-
tected a rare splice variant of REST, known as REST4 (Wagoner
et al., 2010), in human breast cancer. However, whereas full-
length REST was readily detectable in all breast cancers
analyzed, the REST4 splice variant was rarely found to be ex-
pressed (Figure S1D). In tumors that express REST4, full-length
RESTmRNAwas also expressed, and REST4mRNA expression
did not correlate with lower REST protein levels (Figure S1D),
indicating that REST protein is not lost in human breast cancer
via this alternative splicing event. Collectively, these data sug-
gest that the REST tumor suppressor protein is posttranscrip-
tionally depleted in human breast cancer.
Discovery of REST Degradation Regulators
Because REST protein was frequently lost in human TNBC
without a concomitant loss of RESTmRNA, we sought to identify
posttranscriptionalmechanismsbywhichRESTmaybecompro-
mised. REST is an unstable protein targeted for proteasomal-
mediated degradation by the E3 ubiquitin ligase SCFbTRCP
(Guardavaccaro et al., 2008; Westbrook et al., 2008). Like other
SCFbTRCP substrates, phosphorylation of REST on a C-terminal
phosphodegron is required for REST degradation (Guardavac-
caro et al., 2008; Westbrook et al., 2008). Thus, we hypothesized
that loss of REST protein in human TNBC may result from
aberrant activation of oneormore kinase(s), orRESTdegradation
regulators (RDRs), leading to inappropriate REST degradation.
To identify putative RDR kinases, we performed an RNAi-based
screen that utilized the fluorescence intensity of an mRFP-REST
fusion protein as a surrogate for relative REST abundance. Cells
were transfected with a library of 1,908 small interfering RNAs
(siRNAs) targeting 636 kinase and kinase-like genes in the human
genome (three siRNAs/gene) and with a plasmid encoding
mRFP-REST or mRFP (Figure 1E). Flow cytometry was used
to identify siRNAs that increased mRFP-REST fluorescence
without affecting control mRFP fluorescence. Depletion of
SCFbTRCP, theREST-ubiquitin ligase, resulted in a 4-fold increase
in mRFP-REST fluorescence without a significant change in the
mRFP fluorescence (red dot, Figure 1F), confirming that mRFP-
REST responds similarly to endogenous REST.
From the primary genetic screen, 74 siRNAs elicited a greater
than 2-fold effect (p < 0.01) on normalized mRFP-REST fluores-
cence. RDR genes were ranked using a modified two-way anal-
ysis of variance to summarize the effects of all siRNAs for each
gene in the screen. We identified ten genes for which multiple
siRNAs increased REST abundance (Figure 1G). Subsequently,
we retested siRNAs for each of these RDRcandidates. These ex-
periments revealed three candidates (PLK1, TEX14, and SCYL1)
for which multiple siRNAs consistently increased mRFP-REST
fluorescence (see Figures 2A and 3A). We focused subsequent
studies on these RDR candidates.
PLK1 Phosphorylates REST and Controls REST
Abundance
In the primary screen and validation experiments, depletion
of Polo-like kinase 1 (PLK1) consistently yielded the strongest
effects on mRFP-REST abundance. PLK1 is a serine/threonine
kinase implicated in phosphorylation and priming of SCFbTRCP-
substrates for ubiquitylation (Moshe et al., 2004; Watanabe
et al., 2004). To confirm that PLK1 controls REST abundance,
we tested whether genetic or pharmacologic inhibition of
PLK1 affected REST levels. PLK1 siRNAs depleted PLK1 protein
(Figure 2B), led to increased mRFP-REST fluorescence (Fig-
ure 2A), and increased endogenous REST protein levels (Fig-
ure 2C). Additionally, the PLK1 inhibitor BI2536 (Steegmaier
et al., 2007) caused a dose-dependent increase in REST
abundance (Figures 2D and 2E), thus ruling out RNAi off-
target effects. Notably, PLK1 depletion significantly increased
REST protein half-life (Figures 2F, S2A, and S2B), indicating
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Figure 1. Discovery of REST Degradation Regulators in Human Breast Cancer
(A) Analysis of REST protein expression. Representative images of normal mammary gland (top, n = 8) and human tumors (n = 185) exhibiting positive REST
expression (middle panel) and lack of REST expression (bottom panel).
(B) REST protein expression is frequently lost in human breast cancer. TheREST IHC scores from (A) are plotted by disease subtype. Each dot represents a tumor;
the black line represents the median. Red dots are tumors with REST IHC score = 0 (19%).
(C) REST protein expression is frequently lost in TNBC. The percentage of tumors within each subtype with undetectable REST protein (REST IHC score = 0) is
shown. TNBC = 32%
(D) REST mRNA and protein levels are not correlated in primary human breast tumors. REST mRNA levels were analyzed in 50 primary breast tumors (from A).
Each dot represents a tumor; the black bar represents the median.
(E) RNAi-based screen for RDR genes. Cells were transfected with siRNAs targeting the kinome (three siRNAs/gene) and the mRFP-REST or mRFP cDNA(n = 4).
Changes in fluorescence were assessed by flow cytometry.
(legend continued on next page)
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PLK1 antagonizes REST abundance by restraining REST protein
stability.
Because PLK1 directly phosphorylates and primes substrates
for SCFbTRCP-mediated ubiquitylation and degradation (Moshe
et al., 2004; Watanabe et al., 2004), we tested whether PLK1 in-
teracts with and phosphorylates REST. To determine whether
PLK1 interacts with REST in cells, we performed bimolecular
fluorescence complementation (BiFC) (Kerppola, 2006). The
C-terminal half of YFP was fused to either the N-terminal or
C-terminal end of PLK1 (C-YFP-PLK1 and PLK1-C-YFP, respec-
tively). These fusion cDNAs were transduced into human mam-
mary epithelial cells (HMECs) engineered to express REST fused
to the N-terminal half of YFP (N-YFP-REST). As indicated by
cellular YFP fluorescence, PLK1 strongly interacts with REST
(Figure 2G). Additionally, PLK1 was coimmunoprecipitated with
a REST-specific antibody in 293T and human TNBC cells (Fig-
ures 2H and S3), suggesting endogenous PLK1 and REST
interact in human breast cancer.
To determine which REST domains are required for interaction
with PLK1, GST-tagged REST fragments were evaluated for
interaction with endogenous PLK1 (Figure 2I). The C terminus
of REST (amino acids 786–1098), which includes the REST phos-
pho-degron, was required for the PLK1 interaction (Figure 2J),
supporting the hypothesis that PLK1 may phosphorylate REST.
To directly test this hypothesis, we performed an in vitro kinase
assay. PurifiedPLK1was incubatedwithRESTprotein fragments
that contain or lack the C-terminal phospho-degron (WT and
Ddegron, respectively). PLK1 preferentially phosphorylated the
RESTWT fragment as compared to the REST Ddegron fragment
(Figure 2K), suggesting PLK1 phosphorylates the REST C termi-
nus. Mass spectrometry revealed that PLK1 phosphorylates
REST on serine 1030 (Figure 2K and Figure S4). Although this
analysis cannot definitively exclude phosphorylation by PLK1
on other phospho-sites within the REST C terminus (Guardavac-
caro et al., 2008; Westbrook et al., 2008), it does indicate that
PLK1 phosphorylates the critical serine within the REST phos-
pho-degron (S1030) that is required for SCFbTRCP-binding, ubiq-
uitylation, and degradation (Westbrook et al., 2008). Collectively,
these data indicate that PLK1 directly phosphorylates the REST
phospho-degron and is a potent regulator of REST stability.
The STP Axis Regulates REST Abundance
In addition to PLK1, the primary genetic screen and subsequent
validation revealed two RDR candidates, TEX14 and SCYL1,
whose depletion consistently increased mRFP-REST fluores-
cence (Figure 1G). siRNA-mediated depletion of TEX14 or
SCYL1 (Figure S5) led to increased levels of mRFP-REST fluo-
rescence and endogenous REST protein in both 293T and
human TNBC cells (Figures 3A and 3B and 5C). Additionally,
depletion of both SCYL1 and TEX14 resulted in a significant in-
crease in REST protein half-life (Figures 3C, S2A, and S2B), sug-
gesting that SCYL1 and TEX14 regulate REST abundance and
stability. Notably, whereas previous observations suggest that,
in some contexts, REST is degraded as cells approach mitosis
(Guardavaccaro et al., 2008), our data indicate that PLK1,
SCYL1, and TEX14 regulate REST dosage and stability without
synchronization in mitosis (Figures 2F and 3C), suggesting that
the SCYL1, TEX14, and PLK1 (STP) axis is capable of controlling
REST protein abundance in interphase cells.
Notably, both TEX14 and SCYL1 encode proteins predicted to
be kinase deficient (based on amino acid sequence; Manning
et al., 2002), suggesting these proteins may play a noncatalytic
role in suppressing REST levels. Because our data strongly sug-
gest that PLK1 is a direct priming kinase for REST degradation,
we hypothesized TEX14 and SCYL1 may govern REST levels by
regulating the physical or functional interaction between PLK1
and REST. To elucidate the mechanism(s) by which TEX14 and
SCYL1 regulate REST protein levels, we tested whether either
candidate interacts with REST in cells. TEX14 and SCYL1 asso-
ciated with both ectopic and endogenous REST by coimmuno-
precipitation (first lane of Figures 3D and 3E, respectively), and
this interaction was conserved in human TNBC cells (Figure S3).
To determine which domains of REST mediate the interaction
with these RDR candidates, we tested associations between
GST-fused REST fragments (Figures 2I and 2J) and endogenous
TEX14 and SCYL1. TEX14 associated with N-terminal zinc fin-
gers within the DNA-binding domain of REST (amino acids
141–419) (Figure 3D). In contrast, SCYL1 interacted with the C
terminus of REST (amino acids 786–1098), which is the same re-
gion required for PLK1 interaction. These data indicate that
SCYL1 and TEX14 associate with different regions of REST
and further suggest that TEX14 and SCYL1 may regulate REST
abundance through interaction with REST protein.
Based on their association with REST, we hypothesized
TEX14 and/or SCYL1 may act as adaptors to bridge REST inter-
action with PLK1. To test this hypothesis, TEX14 or SCYL1 was
depleted by RNAi, and the interaction between REST and PLK1
was examined via coimmunoprecipitation. Depletion of SCYL1
significantly reduced the REST-PLK1 association (Figure 3E).
In contrast, depletion of TEX14 had no observable effect on
the REST-PLK1 interaction (Figure 3E). Additionally, SCYL1,
but not TEX14, is required for the REST-PLK1 interaction in hu-
man TNBC cells (Figure 3F and Figure S6). This suggests
SCYL1 bridges or stabilizes the REST-PLK1 interaction, and
that TEX14 may play other roles in facilitating REST degradation.
Because TEX14 does not mediate the REST-PLK1 interaction,
we asked whether TEX14 functions with PLK1, or alternatively, in
a PLK1-independent pathway to regulate REST abundance.
Although ectopic expression of TEX14 resulted in a significant
decrease in REST protein abundance (Figure 3G, lane 2), inhibi-
tion of PLK1 completely reversed this effect (Figure 3G, lane 4).
Furthermore, mutating the PLK1 phospho-site within the REST
degron (S1030A) ameliorated the effects of TEX14 on REST pro-
tein levels (Figure 3H). Together, these data suggest that TEX14
(F) Primary genetic screen for RDR candidates. The normalized effect of each siRNA onmRFP-REST fluorescence from the primary screen is shown. The red and
blue dots are the mean of the positive control (sibTRCP) and negative control siRNAs, respectively.
(G) Identification of RDR candidate genes. Heatmaps represent the effect (relative change in fluorescence) of individual siRNAs on mRFP fluorescence (left) and
mRFP-REST fluorescence (right). The red gradient represents the relative change in mRFP-REST fluorescence. The genes for which multiple siRNAs increased
REST abundance are shown and those for which multiple siRNAs increased REST abundance upon retesting are labeled in red.
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Figure 2. PLK1 Phosphorylates the REST Degron and Regulates REST Protein Abundance
(A) Depletion of PLK1 increases REST abundance. Cells were transfected with the indicated siRNAs andmRFP-REST (n = 4). Cellular fluorescence was assessed
by flow cytometry. Data are presented as mean ± SE.
(B) Western blot for PLK1 protein levels in cells transfected with the indicated siRNAs.
(C) Depletion of PLK1 increases endogenous REST abundance. 293T cells transfectedwith the indicated siRNAswere treatedwithmonastrol for 8 hr (to enrich for
cells with active PLK1). Endogenous REST protein levels were assessed via western blot.
(D) Pharmacologic inhibition of PLK1 increases REST abundance. 293T cells were treated with BI2536 (PLK1 inhibitor) as shown and transfected with mRFP-
REST (n = 4). Cellular fluorescence was assessed by flow cytometry. Data are presented as mean ± SE.
(legend continued on next page)
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reduces REST protein levels in a manner dependent on PLK1
activity and the REST phospho-degron.
REST ismarked for degradation by the ubiquitin ligase bTRCP,
and the REST phospho-degron serves as a requisite binding site
for bTRCP-REST interaction (Guardavaccaro et al., 2008; West-
brook et al., 2008). However, additional evidence indicates that
bTRCP interacts with some substrates through bipartite surfaces
(Watanabe et al., 2004), suggesting other REST surfaces or inter-
acting proteins may facilitate REST-bTRCP interaction. Thus, we
hypothesized that TEX14, which associates with the N terminus
of REST, may act as an adaptor to bridge REST interaction with
bTRCP. Consistent with this hypothesis, TEX14 associated with
bTRCP by coimmunoprecipitation (Figure 3J, lane 2). We then
determined whether TEX14 (and SCYL1 and PLK1) is required
for the REST-bTRCP interaction. Consistent with their role in
phosphorylating the REST phospho-degron (that facilitates
bTRCP-binding), depletion of PLK1 or SCYL1 significantly
impaired the REST-bTRCP interaction (Figure 3I). Interestingly,
depletion of TEX14 also resulted in a significant reduction in
the REST-bTRCP interaction (Figure 3I), suggesting TEX14 is
also required for bTRCP interaction with REST.
Based on this, we hypothesized TEX14 may regulate REST
levels by facilitating bTRCP-REST interaction. To test this hy-
pothesis, we scanned a series of TEX14 deletion mutants (Mon-
dal et al., 2012) for their ability to reduce REST protein levels.
TEX14 D705–730 (lacking amino acids 705–730) was unable to
negatively regulate REST protein abundance (Figure 3G,
lane 3) as compared to full-length TEX14 (Figure 3G, lane 2).
However, TEX14 D705–730 maintained its ability to associate
with REST (Figure 3J, lane 3), suggesting REST interaction is
not sufficient for TEX14 to regulate REST abundance. Further-
more, in contrast to full-length TEX14, TEX14 D705–730 dis-
played significantly reduced interaction with bTRCP (Figure 3J,
lane 3) and impeded endogenous REST-bTRCP interaction (Fig-
ure 3J, lane 6), suggesting TEX14-bTRCP interaction is required
for bTRCP to interact with REST. Collectively, these data sug-
gest TEX14 regulates REST abundance by facilitating the inter-
action between bTRCP and REST. More broadly, these data
demonstrate that SCYL1, TEX14, and PLK1 function collectively
in a signaling network, the STP axis, to promote bTRCP interac-
tion and REST degradation (see model in Figure 3K).
STPAxis Components Are Amplified and Overexpressed
in Human Breast Cancer
Our data indicate the STP axis negatively regulates the dosage of
the tumor suppressor protein, REST, suggesting components of
the STP axis may themselves function as oncogenes. Thus, we
determined whether SCYL1, TEX14, and/or PLK1 have onco-
genic characteristics and are aberrantly expressed in human
breast cancers by analyzing a publicly available data set of 773
primary human breast tumors and 107 normal human breast tis-
sue (Cancer Genome Atlas, 2012). Notably, TEX14, SCYL1, and
PLK1 were overexpressed (candidate mRNA expression greater
than the 95th percent confidence interval of that in normal mam-
mary gland) in a substantial fraction of human breast cancers
compared to normal human breast tissue samples (TEX14,
29.4%; SCYL1, 41.5%; PLK1, 84.2%) (Figures 4A, 4C, and 4E).
We also compared expression of TEX14, SCYL1, or PLK1
in the subset of breast tumors for which matched normal
mammary tissue is available. Both TEX14 (up to 35-fold) and
PLK1 (up to 93-fold) demonstrated remarkable overexpres-
sion in tumors as compared to normal (Figures 4B and 4F).
SCYL1 exhibited modest overexpression at the mRNA level
(maximum 3.8-fold) (Figure 4D). These data suggest a subset
of breast cancers exhibit significantly elevated expression of
STP components.
Oncogenes are commonly overexpressed via genetic and
epigenetic mechanisms. To determine whether gene amplifi-
cation contributes to the aberrant expression of STP compo-
nents in breast cancer, we compared genomic copy number
and mRNA expression in the same TCGA breast cancer
cohort. TEX14 is frequently amplified in human breast cancers
(9.3%), with 6% of breast cancers harboring TEX14 focal am-
plifications of less than 10 Mb (median 8.2 Mb, Figures S7A
and S7B). Amplifications of SCYL1 were also focal (median
2.6 Mb) but occurred less frequently (2.2% of breast cancers,
Figures S7A and S7C). Notably, TEX14 and SCYL1 exhibited
significant copy-number-associated increases in mRNA
expression (Figures S7E and S7F, respectively), suggesting
amplifications drive aberrant expression of these candidate
oncogenes in a subset of human breast cancers. Although
PLK1 is frequently amplified in human breast cancers
(9.6%), these copy number gains exhibit a median size of
27.5 Mb, with only 0.9% of breast cancers harboring PLK1
amplifications less than 10 Mb (Figures S7A and S7D). The
large size of the amplicon suggests that multiple oncogenic
drivers may exist with PLK1 in this region of chromosome
16. Additionally, in accordance with previous reports of
smaller breast cancer cohorts (Maire et al., 2013), copy num-
ber of the PLK1 locus was not correlated with PLK1 mRNA
levels (Figure S7G). Thus, the frequent overexpression of
PLK1 in human breast cancer is likely driven by other
(E) Pharmacologic inhibition of PLK1 increases endogenous REST abundance. 293T cells were treated with BI2536 or DMSO. Endogenous REST protein levels
were assessed via western blot.
(F) Depletion of PLK1 increases REST protein stability. 293T cells transfected with the indicated siRNAs were treated with cycloheximide and analyzed for REST
protein levels.
(G) PLK1 interacts with REST. HMECs expressing N-YFP-REST were transduced with C-YFP-PLK1 or PLK1-C-YFP retroviruses. Cellular fluorescence was
assessed by flow cytometry. Data are presented as mean ± SE.
(H) Endogenous REST was immunoprecipitated from monastrol-treated 293T cells and analyzed for REST and PLK1 protein by western blot.
(I) GST-REST fragments used for interaction studies. Numbers indicate amino acids included in each fragment.
(J) PLK1 interacts with the C terminus of REST. 293T cells were transfected with the GST-REST fragments from (I). After MG132 treatment (to inhibit proteasome
function), interaction was assessed by GST pull down and western blot for GST (top) and PLK1 (bottom).
(K) REST is phosphorylated by PLK1 on serine 1030. Purified REST protein fragments (wild-type or Ddegron) were incubated with active PLK1 and ATP [g32P].
Audioradiography and mass spectrometry were performed. The serine within the REST phospho-degron phosphorylated by PLK1 is highlighted.
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Figure 3. The STP Axis Regulates REST Abundance
(A) Depletion of SCYL1 and TEX14 increases REST abundance. Cells were transfected with the indicated siRNAs and mRFP-REST (n = 4). Cellular fluorescence
was assessed by flow cytometry. Data are presented as mean ± SE.
(B) Depletion of SCYL1 and TEX14 increases endogenous REST abundance. 293T cells transfected with the indicated siRNAs were treated with monastrol and
endogenous REST protein was assessed via western blot.
(C) Depletion of SCYL1 and TEX14 increases REST protein stability. 293T cells transfected with the indicated siRNA were treated with cycloheximide for as
shown. REST protein levels were assessed by western blot.
(D) SCYL1 interacts with the C terminus of RESTwhereas TEX14 interacts with the N terminus of REST. 293T cells were transfectedwith theGST-REST fragments
(Figure 2I). After MG132 treatment, interaction was assessed by GST pull-down and western blot.
(legend continued on next page)
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mechanisms. Collectively, these data suggest STP compo-
nents have oncogenic characteristics and are frequently over-
expressed in human breast cancer by both genetic and epige-
netic mechanisms.
The STP Axis Supports the Transformed State of TNBC
Cells by Restraining REST
The observations described above implicate the STP axis as an
oncogenic mechanism by which REST protein levels and func-
tion is suppressed in human TNBC. Thus, we hypothesized the
STP axis may support the transformed state of TNBC cells
by restraining REST. Because of the many described functions
of PLK1 and potential pleiotropic effects of PLK1 inhibition
(Lens et al., 2010; Petronczki et al., 2008), we tested this
hypothesis by altering STP axis function via SCYL1 or TEX14
gain or loss of function and measuring the effect on TNBC
cell transformation. Ectopic expression of SCYL1 and TEX14
in TNBC cells (that exhibit low transformation potential) resulted
in a decrease in REST abundance (Figure 5A, lane 2) and an
increase in anchorage-independent proliferation (Figure 5B),
indicating that SCYL1 and TEX14 promote TNBC cell transfor-
mation. Additionally, these data suggest that the aberrant over-
expression of SCYL1 and TEX14 observed in human breast
tumors may be a pathogenic mechanism driving transforma-
tion. Our model predicts SCYL1 and TEX14 promote cellular
transformation through negative regulation of the REST tumor
suppressor. Indeed, restoring REST levels/function (Figure 5A,
lane 3) strongly suppressed TEX14- and SCYL1-mediated
anchorage-independent proliferation in TNBC cells (Figure 5B),
suggesting TEX14 and SCYL1 can promote TNBC cell transfor-
mation by reducing levels of the REST tumor suppressor
protein.
To determine whether endogenous TEX14 or SCYL1 supports
the transformed state of TNBC cells, we depleted TEX14 or
SCYL1 by RNAi and measured the effects on anchorage inde-
pendent proliferation in TNBC cells. Notably, inhibition of
TEX14 or SCYL1 led to an increase in endogenous REST protein
levels (Figure 5C) and a concomitant decrease in anchorage-
independent proliferation (Figure 5D). Moreover, depletion of
REST reversed the effects of SCYL1 and TEX14 depletion and
restored TNBC cell transformation (Figures 5E and 5F). Taken
together, these data suggest that the STP axis promotes trans-
formation of TNBC cells by restraining REST tumor suppressor
function.
Inhibition of the STP-REST Axis Impairs Tumorigenicity
and Metastatic Proclivity of TNBC
Our observations suggest TNBC cells are dependent on the STP
axis to maintain low REST levels and the transformed state. To
test whether the STP axis is required for the tumorigenic and
metastatic potential of TNBC cells, we engineered the highly
tumorigenic and metastatic TNBC cell line MDA-MB231-LM2
(Minn et al., 2005) to inducibly express dual small hairpin RNAs
(shRNAs) targeting TEX14 and SCYL1. We chose to disrupt
both SCYL1 and TEX14 function to more significantly interfere
with REST degradation. Indeed, combined depletion of TEX14
andSCYL1 resulted in amore significant increase in endogenous
REST protein levels (Figure 6A) and a more substantial reduction
in anchorage-independent proliferation (Figure 6B) compared to
depletion of either TEX14orSCYL1alone (seeFigures 5Eand5F).
To assess the effect of TEX14 and SCYL1 on TNBC tumorige-
nicity, we used a barcode-based competition assay (Figure 6C)
that enables one to compare the relative fitness of tumor cells
harboring different shRNAs within a single tumor while control-
ling for intermouse and intertumor variability. MDA-MB231-
LM2 cells harboring an inducible negative control shRNA or
combination shTEX14+shSCYL1 were mixed at equal cell ratios
and transplanted into immunocompromised mice maintained in
the presence or absence of dox. The relative abundance of each
population was quantified from the genomic DNA of resultant
tumors via barcode abundance. Notably, tumor cells harboring
combination shTEX14+shSCYL1 consistently dropped out of
the tumor population selectively in the presence of dox (Fig-
ure 6D). This strongly suggests that loss of TEX14 and SCYL1
function impairs TNBC cell fitness and tumorigenic potential.
In addition to their aggressive tumorigenic potential, TNBCs
are known to metastasize to visceral organs such as the lungs
(Di Cosimo and Baselga, 2010; Smid et al., 2008). To directly
assess the effects of STP axis inhibition on TNBC metastatic
colonization and expansion, we measured the effects of TEX14
and SCYL1 depletion in the context of an experimental metas-
tasis model (tail vein injection) using the same barcode-based
competition method described above. Once significant tumor
burden was observed in the lung (using bioluminescence imag-
ing), the relative abundance of tumor cells with negative control
shRNA or combination shTEX14+shSCYL1 were quantified via
barcode abundance. As shown in Figure 6E, dox-dependent
depletion of TEX14 and SCYL1 significantly reduced fitness
of these TNBC lung metastases. Although these data do not
(E) SCYL1 is required for the PLK1-REST interaction. Endogenous REST was immunoprecipitated from monastrol-treated 293T cells transfected with the
indicated siRNAs and analyzed via western blot.
(F) SCYL1 is required for the PLK1-REST interaction in human TNBC cells. BT549 TNBC cells were treated with MLN4924 (to inhibit REST-ubiquitination) and
transfected with the indicated siRNAs. Endogenous REST was immunoprecipitated and analyzed via western blot.
(G) TEX14-mediated regulation of REST abundance requires TEX14 amino acids 705–730. 293T cells were transfectedwith the indicated FLAG-TEX14 constructs
and treated with the BI2536. Western blot analysis was performed for REST and actin (loading control).
(H) TEX14 regulates REST abundance through the PLK1-phosphorylated REST-degron. 293T cells were transfected with the indicated expression vectors and
treated with monastrol. Western blot analysis was performed for REST, TEX14, and actin (loading control).
(I) TEX14 is required for the REST-bTRCP interaction. Endogenous REST was immunoprecipitated from MLN4924-treated 293T cells transfected with the
indicated siRNAs and analyzed via western blot.
(J) TEX14 links REST and bTRCP. MLN4924-treated 293T cells were transfected with the indicated FLAG-TEX14 constructs. FLAG-TEX14 or endogenous REST
was immunoprecipitated and analyzed via western blot analysis.
(K) Model of REST regulation by the STP axis. The STP axis (SCYL1-TEX14-PLK1) cooperates to regulate REST phosphorylation and bTRCP recruitment. REST is
subsequently targeted for degradation by SCFbTRCP.
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Figure 4. STP Axis Components Are Aberrantly Overexpressed in Human Breast Cancer Compared to Normal Mammary Tissue
(A, C, and E) TEX14, SCYL1, and PLK1 expression in normal mammary tissue and breast tumors. Expression level of the indicated gene (represented as log2
FPKM [fragments per kilobase per million fragments mapped]) in each normal and tumor sample in the TCGA data set is plotted. The 95% confidence interval for
the normal samples is represented by the green dashed line.
(B, D, and F) TEX14, SCYL1, and PLK1 expression is higher in tumors than matched normal. The expression level of the indicated gene is shown for each tumor
normal pair in the TCGA data set (represented as FPKM).
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address the role of the STP axis in the early stages of metastasis,
these data support the model that TNBC cells are dependent on
TEX14 and SCYL1 for their survival and expansion in the lung.
Collectively, these data suggest that STP axis supports TNBC
cell fitness in both primary and metastatic tumors.
The STP Axis Correlates with Low REST Protein Levels
and Poor Patient Outcome in Breast Cancer
Taken together, our functional data suggest that some breast
cancers are dependent on the STP axis for their tumorigenic
and metastatic behavior. This hypothesis predicts that breast
cancers with high STP axis activity may exhibit poor clinical
outcome. Because the STP axis may have broad downstream
effects on gene expression, we tested this hypothesis by (1)
A
B
E F
D
C Figure 5. The STP Axis Supports the Trans-
formed State of Breast Cancer by Restrain-
ing REST
(A) Ectopic SCYL1 and TEX14 reduce endogenous
REST protein abundance. BT549 TNBC cells
were transduced as indicated and analyzed by
western blot.
(B) SCYL1 and TEX14 promote cellular
transformation in a REST-dependent manner.
Anchorage-independent growth was assessed in
thecells from (A).Data are presentedasmean±SE.
(C) SCYL1 and TEX14 loss of function increases
REST protein abundance. MDA-MB231-LM2
TNBC cells were engineered with the indicated
dox-inducible shRNAs. Protein levels were as-
sessed by western blot analysis.
(D) SCYL1 and TEX14 loss of function suppresses
cellular transformation. Anchorage-independent
growth was assessed in the cells from (C) ± dox.
Data are presented as mean ± SE.
(E) SCYL1 and TEX14 support the transformed
state by restraining REST. MDA-MB231-LM2
TNBC cells engineered with the indicated dox-
inducible shRNAs (from C) were transduced with a
constitutive control or REST shRNA retrovirus.
Protein levels were assessed by western blot.
(F) SCYL1 and TEX14 support the transformed
state by restraining REST. Anchorage-indepen-
dent growth was assessed in the cells from
(E) ± dox. Data are presented as mean ± SE.
defining a transcriptional signature that
correlates with SCYL1, TEX14, and
PLK1 expression, and subsequently (2)
testing the correlation of this STP signa-
ture on independent data sets with long-
term clinical follow-up. To define an STP
signature, we used coexpression ana-
lyses to compute a gene set strongly
correlated with STP expression in diverse
human samples. Using the TCGARNaseq
data set, we identified a gene signature
whose expression significantly correlates
with SCYL1, TEX14, and PLK1 across
773 primary human breast tumors.
Expression of the STP signature was
higher in TNBCs (Figure 7A) consistent with more frequent loss
of REST protein in this subtype of breast cancers. Next, we
compiled breast cancer data sets (n = 1,151 patients) for which
gene expression data (Affymetrix U133 platform only) and
metastasis free survival data were available. Notably, patients
with tumors harboring high STP signature had significantly worse
distant metastasis-free survival than those with low STP signa-
ture (Figure 7B, p < 1.0 3 108). Furthermore, whereas STP
expression correlates with the TNBC subtype, the STP signature
also exhibited prognostic value independent of breast cancer
subtype (Figure 7C, p = 0.019).
Our data indicate that the STP axis functions to inhibit
REST protein accumulation. If the STP axis contributes to the
frequent downregulation of REST protein seen in breast cancer
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(Figures 1B and 1C), expression of STP components should
inversely correlate with REST protein levels in human breast tu-
mors. To test this hypothesis, we quantified the mRNA levels of
each STP axis component in a subset of the primary human tu-
mors (n = 50) previously analyzed for REST protein levels (see
Figures 1B and 1C). Because each member of the STP axis reg-
ulates REST abundance, we summed the normalized expression
level of SCYL1, TEX14, and PLK1 into one cumulative STP
expression value. Higher expression of the STP axis compo-
nents strongly correlates with low REST protein levels (Fig-
ure 7D), suggesting this pathway negatively regulates REST
protein levels in human breast cancer. Combined with our func-
tional data, these data suggest that the STP axis supports the
pathogenicity of TNBCs, at least in part, by reducing REST pro-
tein levels and function.
DISCUSSION
The STP-REST Axis as a Driver of TNBC
TNBC is a collection of diseases with heterogeneous molecular
features (Prat and Perou, 2011). Indeed, recent analyses of
copy number variation and somatic mutations have revealed
very few drivers that are common across TNBCs (Cancer
Genome Atlas, 2012; Curtis et al., 2012). Such genetic heteroge-
neity has called into question whether there are common patho-
genic mechanisms (and potential therapeutic targets) driving the
TNBC subtype(s) of breast cancer (Brough et al., 2011; Collisson
et al., 2012). Herein, we present evidence of an oncogene-tumor
suppressor network that is frequently compromised in TNBC.
Specifically, we demonstrate that the REST tumor suppressor
is posttranscriptionally inactivated in human breast cancer,
most commonly in TNBC. Using an unbiased genetic approach,
we discovered the oncogenic STP axis (SCYL1, TEX14, and
PLK1) that functions collectively to suppress REST protein levels
via degradation. Components of this signaling axis are overex-
pressed in aggressive TNBCs and are required to support the
transformed state of TNBC cells, at least in part, through nega-
tive regulation of the REST tumor suppressor protein. Notably,
high STP axis expression correlates with low REST protein levels
and poor clinical outcome in human breast cancers. Our data
suggest that inactivation of REST (via protein degradation) may
be a common driver of TNBC pathogenesis, and that the STP
axis is a mediator of this REST dysfunction.
Neural Programs in Breast Cancer
Cancers often usurp developmental programs or signaling path-
ways during tumor inception and progression (e.g., Yang and
Weinberg, 2008). During normal embyrogenesis, REST serves
as a master repressor of neural transcriptional programs and
neural differentiation (Ballas et al., 2005). Our finding that REST
is posttranscriptionally inactivated in TNBC and other breast
cancers raises the important question of whether signaling net-
works promoting neural phenotypes are misregulated in and
contribute to breast cancer pathogenesis. Indeed, many aspects
of neural programs are misexpressed in human breast cancers.
For example, neurotrophic receptors and their cognate ligands
are commonly misexpressed in TNBC and other breast cancers
and contribute to tumor growth and survival signaling (Davidson
et al., 2004; Dolle´ et al., 2003; Hondermarck, 2012; Lagadec
et al., 2009). Many of these neurotrophic receptors and ligands
are targets of the REST repressor (Johnson et al., 2007). Our
data are consistent with a model in which dysfunction of the
A
D E
B C Figure 6. The STP-REST Axis Is Required for
Primary Tumor Growth and Metastatic
Expansion
(A) MDA-MB231-LM2 TNBC cells were engineered
to inducibly coexpress SCYL1 and TEX14 shRNAs.
Protein levels were analyzed by western blot.
(B) Depletion of SCYL1 and TEX14 impairs
anchorage-independent growth. Cells from (A)
were assessed for anchorage-independent growth.
Data are presented as mean ± SE.
(C) In vivo barcode-based competition assay
schematic. MDA-MB231-LM2 cells expressing
inducible negative control shRNA or combination
shTEX14+shSCYL1 were mixed at an equal ratio.
This population was transplanted into mice, and
tumors were allowed to form ± dox. At the exper-
imental end point, genomic DNA was collected,
and the relative abundance of each cell population
was quantified via barcode-quantitative PCR
(qPCR) analysis.
(D) Depletion of SCYL1 and TEX14 impairs primary
tumor growth. The experiment was carried out as
described in (C). Barcode levels ± dox are shown.
Each dot represents an individual tumor. The black
line represents the median.
(E) Depletion of SCYL1 and TEX14 impairs meta-
static progression. The experiment was carried out
as described in (C), except that the mixed population was intravenously injected and animals were monitored for lung metastatic growth ± dox via biolumi-
nescence imaging. Barcode levels from lung genomic DNA are shown. Each dot represents lung metastases from an individual animal. The black line represents
the median.
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STP-REST axis may contribute to such aberrant neural growth
programs in breast cancer, although this hypothesis requires
further testing.
During development, REST degradation is tightly regulated by
SCFbTRCP-mediated ubiquitination and proteasomal degrada-
tion (Westbrook et al., 2008), and this process requires REST
phosphorylation within its phospho-degron. In the current study,
we have the identified the STP axis that phosphorylates the
REST phospho-degron and controls REST protein degradation
in human breast cancers. It will be important to determine
whether the STP axis similarly controls REST protein levels in
the context of normal development (early neural differentiation
or other adult differentiation programs) or in the pathology of
neurologic disorders as has been reported for casein kinase 1
(Kaneko et al., 2014). We note that, whereas PLK1 has essential
functions across cell types (Archambault and Glover, 2009),
SCYL1 and TEX14 function primarily in the neural and germ
cell compartments, respectively (Iwamori et al., 2010; Schmidt
et al., 2007; Wu et al., 2003), suggesting developmental restric-
tions in their function. Importantly, changes in REST protein
levels play causative roles in the response to neurologic insult
(e.g., ischemia) and neurodegenerative disorders such as Hun-
tington’s disease and Alzheimer’s disease (Calderone et al.,
2003; Lu et al., 2014; Zuccato et al., 2003). Although STP com-
ponents are clearly misregulated at the genetic level (i.e., ampli-
fication) in human breast cancer, it will be important to determine
if they are similarly misregulated in neurologic pathologies.
New Opportunities for TNBC Therapy
Our discovery that the STP axis supports TNBC tumorigenic and
metastatic proclivity provides new opportunities for therapeutic
entry points for TNBC. It is noteworthy that pharmacologic inhi-
bition of PLK1, one of the STP axis components, has recently
been shown to impair breast cancer progression in preclinical
(animal) models of TNBC (Maire et al., 2013). However, although
several pharmacologic PLK1 inhibitors have been developed,
these inhibitors have not been successfully employed in the
clinic due, in large part, to toxicities in bone-marrow-related tis-
sues and other proliferative compartments (Degenhardt and
Lampkin, 2010; Lens et al., 2010; Scho¨ffski, 2009). PLK1 func-
tions in many diverse signaling pathways and cellular processes,
and the toxicities of PLK1 inhibitors suggest that many of the crit-
ical functions of PLK1 are shared between normal and malignant
cells. Our data raise the important question of whether subset(s)
of PLK1 functions may be specifically required in malignant cells
(versus normal tissues) and thus may be exploited as more
selective anticancer strategies.
Herein, we describe a molecular pathway consisting of PLK1,
SCYL1, and TEX14 that may be specifically required for breast
cancer cell survival. Our data indicate PLK1 operates in
conjunction with SCYL1 and TEX14 to lower protein levels of
the REST tumor suppressor. PLK1 activity increases during
mitosis, which is consistent with previous studies suggesting
that, in some contexts, REST may be degraded as cells transi-
tion through mitosis (Guardavaccaro et al., 2008). The cooper-
ation between PLK1 and SCYL1 and TEX14 suggests there
may be a relationship between the STP-REST axis and progres-
sion into or through mitosis, although future studies are required
to explore the temporal and spatial regulation of REST degrada-
tion by the STP axis and its relation to mitotic progression.
Importantly, inhibition of the STP axis strongly inhibits the
fitness of TNBC cells in vitro and in vivo. Although inhibition
A B
C D
Figure 7. The STP Axis Correlates with Low
REST Protein Levels and Poor Patient
Outcome in Human Breast Cancer
(A) STP axis expression is correlated with TNBC
subtype. The STP axis gene expression signature
for each tumor was plotted by histologic subtype.
The solid line represents the median. The boxes
represent the 25th to 75th percentiles. Error bars
represent 95% confidence interval. Outliers are
represented as circles.
(B) STP axis expression correlates with poor pa-
tient outcome. Patients with the highest and lowest
tertiles of STP axis gene expression signature are
shown in red and blue, respectively (n = 1,151).
(C) STP axis expression correlates with increased
metastatic recurrence in breast cancer patients.
Hazard regression results for the STP expression
signature are shown. Top: results for the STP
signature alone. Bottom: results with an inference
of PAM50 subtype.
(D) STP axis expression and REST protein levels
are inversely correlated in human breast cancer.
The normalized cumulative expression of SCYL1,
TEX14, and PLK1 is shown for tumors exhibiting
REST high and REST low protein (as determined by
IHC). The red line represents the median. The
boxes represent the 25th to 75th percentiles. Error
bars represent 95% confidence interval. Outliers
are represented as circles.
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of PLK1 likely impairs normal and malignant cell viability via
numerous mechanisms, inhibition of SCYL1 and TEX14 is dele-
terious to TNBC cells in a REST-dependent manner. Notably,
increasing REST dosage significantly impairs the viability of
TNBC and other cancer cell types (Gurrola-Diaz et al., 2003;
Watanabe et al., 2006; Westbrook et al., 2005) but does not
affect the fitness of normal adult cell types (Westbrook et al.,
2008). Therefore, impairing the ability of PLK1 to reduce REST
levels may be selectively deleterious to breast cancer cells
(relative to normal tissues), while leaving the other cell essential
functions of PLK1 intact. It will be important to test whether in-
hibition of TEX14 or SCYL1 function(s) has a wider therapeutic
window than PLK1 inhibitors. Collectively, our studies identify
the STP-REST axis as a new vulnerability in TNBC and warrant
further exploration of whether this axis can be therapeutically
exploited.
EXPERIMENTAL PROCEDURES
All mice were maintained and treated in accordance with the NIH Guide for the
Care and Use of Experimental Animals with approval from the BCM Institu-
tional Animal Care and Use Committee.
siRNA Screen and Transfections
For the primary screen, Invitrogen’s Stealth Kinase siRNA library was used
(three siRNAs per gene, individually arrayed). 293T cells were transfected in
96-well format with 40 nM siRNA using oligofectamine (Invitrogen) as recom-
mended by the manufacturer. On the subsequent day, cells were transfected
with CMV-mRFP-REST or CMV-mRFP plasmids (Westbrook et al., 2008) in
quadruplicate using MIRUS Bio’s TransIT 293 under the manufacturer’s rec-
ommended conditions. Cells were analyzed for mRFP fluorescence after
48 hr using flow cytometry. The effects of each siRNA were normalized to
mRFP and to the negative control.
Subsequent siRNA transfections were performed as described above.
The Invitrogen Stealth siRNAs used were GC Medium (negative control,
Invitrogen); FBXW11 (positive control, HSS118532); PLK1-1 (VHS50337);
PLK1-2 (VHS50338); PLK1-3 (VHS50340); TEX14-1 (HSS125434); TEX14-2
(HSS125435); SCYL1-1 (HSS126244); and SCYL1-2 (HSS126245).
Anchorage-Independent Proliferation Assays
For ectopic expression experiments, BT549 and MDA-MB231-LM2 breast
cancer cells were transduced in the presence of 8 ug/ml polybrene and
selected with the appropriate antibiotic. BT549 breast cancer cells (1 3 104)
and MDA-MB231-LM2 breast cancer cells (1.5 3 104) were seeded per
6 cm dish with a bottom layer of 0.6% agarose or noble agar in DMEM and
a top layer of 0.3% agarose or noble agar in DMEM + 10% fetal bovine serum,
respectively. For shRNA experiments, MDA-MB231-LM2 breast cancer cells
were transduced at equivalent multiplicity of infection (1.5) for each shRNA.
Cells were treated with dox for 36 hr prior to seeding. All experiments were
done in triplicate.
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